Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CCR8 | P51685 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14037432 | 1.00 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1CCR8 | |
| SCHEMBL13177349 | 1.00 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1CCR8 | |
| SCHEMBL853539 | 1.00 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1CCR8 | |
| SCHEMBL853540 | 1.00 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1CCR8 | |
| SCHEMBL2930905 | 0.96 | USP30 (0.59) | USP30L3MBTL1ATMALDH1A1CCR8 | |
| SCHEMBL2930907 | 0.96 | USP30 (0.59) | USP30L3MBTL1ATMALDH1A1CCR8 | |
| SCHEMBL22392269 | 0.94 | USP30 (0.58) | USP30L3MBTL1ATMALDH1A1CCR8 | |
| SCHEMBL22392270 | 0.94 | USP30 (0.58) | USP30L3MBTL1ATMALDH1A1CCR8 | |
| SCHEMBL22402113 | 0.94 | USP30 (0.58) | USP30L3MBTL1ATMALDH1A1CCR8 | |
| SCHEMBL10054589 | 0.94 | USP30 (0.58) | USP30L3MBTL1ATMALDH1A1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872141-B2 | Processes for the manufacture of a pyrrolidine-3,4-dicarboxamide derivative | HOFFMANN-LA ROCHE INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872141-B2 | Processes for the manufacture of a pyrrolidine-3,4-dicarboxamide derivative | HOFFMANN-LA ROCHE INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872141-B2 | Processes for the manufacture of a pyrrolidine-3,4-dicarboxamide derivative | HOFFMANN-LA ROCHE INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2155723-A2 | NEW SOLID FORMS OF FXA INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20090215826-A1 | SOLID FORMS OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | ADAM JEAN-MICHEL | 2009-08-27 | — | — | US | disclosed |
| US-20090215826-A1 | SOLID FORMS OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | ADAM JEAN-MICHEL | 2009-08-27 | — | — | US | disclosed |
| US-20090215826-A1 | SOLID FORMS OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | ADAM JEAN-MICHEL | 2009-08-27 | — | — | US | disclosed |
| US-7550487-B2 | Pyrrolidine-3,4-dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550487-B2 | Pyrrolidine-3,4-dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550487-B2 | Pyrrolidine-3,4-dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2008138754-A2 | NEW SOLID FORMS OF FXA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| EP-1732918-B1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080214826-A1 | PROCESSES FOR THE MANUFACTURE OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | HOFFMANN-LA ROCHE, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214826-A1 | PROCESSES FOR THE MANUFACTURE OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | HOFFMANN-LA ROCHE, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214826-A1 | PROCESSES FOR THE MANUFACTURE OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | HOFFMANN-LA ROCHE, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008077797-A1 | PROCESSES FOR THE PREPARATION OF (3R, 4R) -N- (4 -CHLOROPHENYL) -1- (2, 2-DIFLUOROETHYL) -N' - [2-FLUORO-4- (2-OXO-1 (2H) -PYRIDINYL) PHENYL] -3, 4-PYRROLIDINEDICARBOXAMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| EP-1732918-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092881-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092881-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F9, F2, F12 | USP30 3227/4885L3MBTL1 4664/4885ATM 2291/4885 |
| US-20090215826-A1 | SOLID FORMS OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | F2, PEPD, SERPINC1 | USP30 2295/4885L3MBTL1 4054/4885ATM 2474/4885 |
| US-20080214826-A1 | PROCESSES FOR THE MANUFACTURE OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | ALDH18A1, CPS1, DHPS | USP30 2633/4885L3MBTL1 4762/4885ATM 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.